The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

Almost immediately after former US president Joe Biden's office announced he had been diagnosed with an aggressive prostate ...

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable ...

See what infectious disease doctors have to say as government officials appear poised to scale back COVID vaccines and the ...

Federal health agencies were alerted in February 2021 to "large reports of myocarditis" in young people who received the ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

The FDA has approved the Novavax Covid-19 vaccine, but with restrictions, limiting its use to older adults and those over 12 ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...